Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome
| Autor: | Elihu H. Estey, Wanlong Ma, Benjamin N. Bekele, Hagop M. Kantarjian, Zhong J. Zhang, Maher Albitar, Jorge E. Cortes, Amber C. Donahue, Zeev Estrov, Francis J. Giles, Susan O'Brien, Xi Zhang, Michael J. Keating |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Oncology Proteasome Endopeptidase Complex Cancer Research medicine.medical_specialty Adolescent Biology Article Young Adult Risk Factors hemic and lymphatic diseases Internal medicine medicine Chymotrypsin Humans Trypsin Risk factor Survival analysis Aged Neoplasm Staging Aged 80 and over Proportional hazards model Beta-2 microglobulin Myelodysplastic syndromes Cancer Myeloid leukemia Middle Aged Prognosis medicine.disease Survival Analysis Leukemia Myeloid Caspases Myelodysplastic Syndromes Acute Disease Multivariate Analysis Immunology Biomarker (medicine) Female |
| Zdroj: | Clinical Cancer Research. 15:3820-3826 |
| ISSN: | 1557-3265 1078-0432 |
| Popis: | Purpose: Cytogenetic abnormalities are currently the most important predictors of response and clinical outcome for patients with acute myeloid leukemia (AML) or advanced-stage myelodysplastic syndrome (MDS). Because clinical outcomes vary markedly within cytogenetic subgroups, additional biological markers are needed for risk stratification. Experimental Design: We assessed the utility of measuring pretreatment proteasome chymotrypsin-like, caspase-like, and trypsin-like activities in plasma to predict response and survival of patients with AML (n = 174) or advanced-stage MDS (n = 52). Results: All three enzymatic activities were significantly (P < 0.001) increased in the plasma of patients with AML and MDS compared with normal controls. Both chymotrypsin-like and caspase-like activities, but not trypsin-like activity, correlated with outcome. Chymotrypsin-like and caspase-like activities, but not trypsin-like activity, predicted response in univariate analysis (P = 0.002). However, only chymotrypsin-like activity was independent predictor of response from age grouping ( Conclusions: Measuring plasma chymotrypsin-like activity may provide a powerful biomarker for risk stratification in patients with AML and advanced-stage MDS, including those with normal karyotype. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|